Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Acquired by Covestor Ltd

Covestor Ltd increased its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 15.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,702 shares of the specialty pharmaceutical company’s stock after purchasing an additional 358 shares during the period. Covestor Ltd’s holdings in Supernus Pharmaceuticals were worth $92,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. QRG Capital Management Inc. boosted its position in shares of Supernus Pharmaceuticals by 2.6% during the 4th quarter. QRG Capital Management Inc. now owns 15,489 shares of the specialty pharmaceutical company’s stock worth $448,000 after acquiring an additional 398 shares in the last quarter. Texas Permanent School Fund Corp boosted its holdings in Supernus Pharmaceuticals by 1.3% in the first quarter. Texas Permanent School Fund Corp now owns 47,814 shares of the specialty pharmaceutical company’s stock valued at $1,631,000 after purchasing an additional 619 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Supernus Pharmaceuticals by 3.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 23,809 shares of the specialty pharmaceutical company’s stock valued at $689,000 after purchasing an additional 872 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Supernus Pharmaceuticals by 9.1% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,858 shares of the specialty pharmaceutical company’s stock worth $314,000 after purchasing an additional 909 shares in the last quarter. Finally, Fidelis Capital Partners LLC purchased a new stake in shares of Supernus Pharmaceuticals during the 1st quarter worth approximately $33,000.

Supernus Pharmaceuticals Price Performance

Shares of Supernus Pharmaceuticals stock traded up $0.35 during trading hours on Wednesday, hitting $30.25. The company had a trading volume of 140,157 shares, compared to its average volume of 472,103. The company’s 50-day moving average is $27.42 and its two-hundred day moving average is $29.23. The company has a market cap of $1.66 billion, a P/E ratio of -103.10 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a twelve month low of $21.99 and a twelve month high of $35.44.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.